scorecardresearch
Add as a preferred source on Google
Friday, March 27, 2026
TopicCovishield

Topic: Covishield

Death & the Covid vaccine: Why SC has directed govt to frame a ‘no-fault’ compensation scheme

SC was hearing pleas by grieving families who claimed their loved ones died due to adverse events linked to Covid vaccination. Govt denied direct link between vaccines & deaths.

Akhilesh’s claims about Covishield vaccine are baseless, says Union MoS for health SP Singh Baghel

SP chief has been raising alarm about Oxford-AstraZeneca vaccine, but Baghel points to WHO approval. Minister also confident of retaining his Agra seat, which is voting Tuesday.

How safe is AstraZeneca Covid vaccine & why there is no need to panic — some key questions answered

51 cases have been lodged in a UK court against biopharma company over claims that its Covid vaccine caused death and injury in several cases.

Don’t let anti-vaxxers weaponise AstraZeneca furore. Vaccines are safe—and we are the proof

Vaccines have eliminated two diseases—smallpox in humans and rinderpest in cattle. If they were killing one in 50,000 people, we wouldn’t be rolling them out across the globe for decades.

AstraZeneca vaccine safe, effective in kids, finds Lancet study. WHO still says for adults only

The vaccine, marketed as Covishield in India, induced antibody concentrations in children similar to those associated with high efficacy in adults, says study by UK researchers.

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

On Camera

Why SC stand on Scheduled Caste conversion signals a structural reset in India

British Colonial censuses did not merely record caste, they froze it, standardised it, and permanently tied it to governance. Independent India inherited this mechanism.

India’s strategic oil reserves tell a tale of structural constraints & stalled expansion. Here’s why

India’s oil reserves, which can last just 74-75 days, are much less than other major economies. Japan, for instance, holds reserves for 254 days.

India-Japan to finalise deal to co-develop & co-produce UNICORN mast ‘soon’, says Japanese envoy

The countries signed a memorandum for co-development of UNICORN masts in November 2024. India has been second Asian nation to have such an agreement with Tokyo, after Philippines.

The Vishwaguru delusion, mine vs yours, is ruining our view of the world

One side thinks India is punching way above its weight. The other thinks Modi has undermined India and it punches below its strength. Both are wrong.